Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Liberty Media Corporation Series C Liberty Formula One Common Stock (FWONK) vs ImmunityBio Inc. Common Stock (IBRX) Price & Performance

Liberty Media Corporation Series C Liberty Formula One Common StockTrade
ImmunityBio Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Liberty Media Corporation Series C Liberty Formula One Common Stock vs ImmunityBio Inc. Common Stock — how do they compare? Liberty Media Corporation Series C Liberty Formula One Common Stock trades at $90.85 (market cap $23.11B), while ImmunityBio Inc. Common Stock trades at $10.09 (market cap $10.39B). The key difference: Liberty Media Corporation Series C Liberty Formula One Common Stock is far larger — about 2.2× ImmunityBio Inc. Common Stock's market cap, and ImmunityBio Inc. Common Stock is trading nearer its 52-week high, Liberty Media Corporation Series C Liberty Formula One Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Liberty Media Corporation Series C Liberty Formula One Common Stock for 0 Days and ImmunityBio Inc. Common Stock for 6 Days on average.

FWONKIBRX
Market Cap
$23.11B$10.39B
Volume
3,394,59611,509,049
Sector
MediaHealth
52-Week High
$106.66$11.55
52-Week Low
$81.42$1.98
Typical Hold Time
0 Days6 Days
Enterprise Value
$26.57B$10.84B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Liberty Media Corporation Series C Liberty Formula One Common Stock

No Aura AI signal available yet.

ImmunityBio Inc. Common Stock

ImmunityBio (IBRX) trades at $9.80, down 3.16% on the day, amid a bullish technical setup and strong analyst support. The company reported revenue growth to $166 million in 2026 but remains deeply unprofitable with a net loss of $992 million. Recent FDA approval expansion for ANKTIVA in bladder cancer and high-profile executive appointments signal operational momentum, though cash burn remains a concern with negative operating cash flow.

Outlook is cautiously optimistic given the unanimous buy ratings and regulatory milestones, but investment carries high risk due to persistent losses, heavy reliance on financing, and competitive pressures. The stock's trajectory hinges on successful commercialization and pipeline execution to achieve profitability.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FWONK
100% Buy0% Sell
Avg holding period · 0 Days
IBRX

No sentiment data available yet.

About Liberty Media Corporation Series C Liberty Formula One Common Stock

Liberty Media Corporation's Series C Liberty Formula One common stock is a tracking stock reflecting the economic performance of the Formula One Group, which holds Liberty Media's interests in Formula 1 racing, MotoGP, and related minority investments.

Read more on FWONK →

About ImmunityBio Inc. Common Stock

ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.

Read more on IBRX →